SEP 26, 2017 06:00 AM PDT

WEBINAR: From Research to Routine - developing and delivering multiplexed protein mass spectrometry based tests of clinical utility

  • Professor of Proteomics, Founder, CEO and CSO Atturos Ltd. C/O UCD Conway Institute University College Dublin
      Steve is Professor of Proteomics at University College Dublin, Ireland. A chemist (Imperial College, London) and PhD biochemist (University of Cambridge) by training.

      Through engagement in a series of collaborations and international consortia, his current biomedical proteomics research is directed to the discovery and development of protein biomarkers. On-going projects are focussed on the mass spectrometry based measurement and evaluation of protein biomarkers in oncology and inflammatory disease to progress them to clinical utility. Steve's team are also investigating the mechanisms of disease progression focussing on prostate cancer and psoriatic arthritis.

      Steve is highly energetic and enthusiastic with an innovative, open and inclusive approach to his work. He has given over 200 invited presentations at international events, published over 80 scientific papers, edited and contributed to several books including editing one of the first books on Proteomics that was translated into Chinese and Japanese. Steve has held roles as a committee member in the British Society for Proteome Research (currently vice-President, and the European Proteomics Association. He is the lead organiser of the forthcoming annual world congress of the Human Proteome Organisation (HUPO) that will be held in the national Convention Centre in Dublin from 17-21st September 2017 (

      Recently, Steve founded the UCD spinout company 'Atturos' (Dec 2016) to support the delivery of OCProDx to clinical use. OCProDx is a prostate cancer blood-based biomarker test that has the capability to distinguish patients with organ-confined and non-organ confined disease. The test will help inform men diagnosed with prostate cancer whether they should go on or stay on 'active surveillance' The Atturos team has the expertise and experience to deliver this and other multiplexed protein biomarker tests to market.


    DATE: September 26, 2017
    TIME: 6:00AM PDT

    Despite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers, the number of biomarkers that have been developed to the stage of being used routinely in clinical practice is disappointingly low. So, it's clear that whilst there’s huge interest in the development of new biomarkers and major drivers for this to happen: including the pharmaceutical industry’s need to better stratify patients for effective treatment, as yet biomarker development and delivery is proving very challenging.


    This presentation will cover:

    Start at the end: identifying clinical need

    Protein biomarker discovery

    From candidate protein biomarkers to peptide MRM assays – advantages for biomarker evaluation

    Delivery of robust and routine peptide MRM assays – from sample preparation to test report     


    While further work is still needed, the role of Agilent solutions in each of these key research stages will be shown and will support our conclusion that the pathway for implementation of peptide MRM assays is relatively straightforward and can be implemented in future clinical diagnostics settings.


    See more about how Agilent is helping Stephen Pennington with his research.

    Don’t miss Stephen Pennington’s presentation at MSACL US in January 2018. Follow Agilent’s Clinical Research LinkedIn page for upcoming MSACL announcements.

    View Agilent’s Proven Solutions for Clinical Research & Forensic Toxicology Compendium.

    If you would like to speak with an Agilent Sales Rep or get a quote, let us know!


    For Research Use Only.  Not for use in diagnostic procedures.

    Show Resources
    Loading Comments...